Holen Sie sich die Stockscreener-App
4.01
0.00%
0.00
Schlusskurs vom Vortag:
$4.01
Offen:
$4.02
24-Stunden-Volumen:
619.83K
Relative Volume:
0.79
Marktkapitalisierung:
$516.57M
Einnahmen:
$201.49M
Nettoeinkommen (Verlust:
$-66.54M
KGV:
-7.716
EPS:
-0.5197
Netto-Cashflow:
$-8.88M
1W Leistung:
+12.32%
1M Leistung:
-8.86%
6M Leistung:
-28.39%
1J Leistung:
+65.70%
1-Tages-Spanne:
$3.96
$4.0677
1-Wochen-Bereich:
$3.52
$4.0677
52-Wochen-Spanne:
$2.43
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Firmenname
Cytek Biosciences Inc
Sektor
Branche
Telefon
(877) 922-9835
Adresse
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.00 | 517.86M | 201.49M | -66.54M | -8.88M | -0.5197 |
ABT
Abbott Laboratories
|
86.53 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
311.99 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.79 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.72 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.69 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-09 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-31 | Herabstufung | Goldman | Buy → Sell |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-07-19 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
Alle ansehen
Cytek Biosciences Inc Aktie (CTKB) Neueste Nachrichten
Cytek Biosciences schedules webinar to advance deep immunophenotyping techniques - Traders Union
Cytek Biosciences (CTKB) director adds 1,454 shares through RSU vesting - Stock Titan
Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock - Stock Titan
Cytek Biosciences (CTKB) CTO vests RSUs, holds 4,919,617 shares - Stock Titan
Cytek Biosciences (CTKB) SVP nets shares after RSU vesting and tax withholding - Stock Titan
Cytek Biosciences (CTKB) CEO reports RSU vesting and tax share withholding - Stock Titan
Cytek (CTKB) CFO nets shares from RSU vesting, surrenders stock for taxes - Stock Titan
Cytek Biosciences (CTKB) CLO gains shares after RSU vesting - Stock Titan
Cytek (CTKB) Q1 2026 Disappoints — EPS $-0.15 Below $-0.10 ViewsCommunity Watchlist Picks - Newser
Cytek Biosciences invites researchers to webinar unveiling novel approach to sterilizing immunity for CDI - Traders Union
CTKB: Millennium-related filers report 6.1% and 5.4% stakes (May 15, 2026) - Stock Titan
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth By Investing.com - Investing.com Australia
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth - Investing.com
Stephens cuts Cytek Biosciences stock price target on elevated costs By Investing.com - Investing.com Nigeria
Stephens cuts Cytek Biosciences stock price target on elevated costs - Investing.com UK
TradingKey - TradingKey
Morgan Stanley Cuts Price Target on Cytek Biosciences to $5.50 From $6, Keeps Equalweight Rating - marketscreener.com
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Cuts Target Price to $4.12 - Moomoo
Cytek Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CTKB) 2026-05-11 - Seeking Alpha
The strategic moves Cytek (CTKB) is making now (Investor Concern) 2026-05-11Dividend Growth - newser.com
Cytek Biosciences Balances Growth Momentum With Cost Pressures - The Globe and Mail
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytek Biosciences, Inc. (CTKB) reports Q1 loss, beats revenue estimates - MSN
Cytek Biosciences (CTKB) Margin Worsening With Q4 Loss Challenges Bullish Narratives - Sahm
Cytek Biosciences Faces Rising Risk From U.S.–China Trade Tensions and Tariff Pressures - TipRanks
Cytek Biosciences Q1 Revenue Increases to $44.1 Million - HarianBasis.co
Cytek (CTKB) Q1 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences, Inc.Common Stock (Nasdaq:CTKB) Stock Quote - FinancialContent
Cytek Biosciences Q1 2026 Financial Results: Revenue, Net Loss, and Key Financial Statements - Minichart
Cytek Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Cytek reaffirms $205M-$212M 2026 revenue outlook as US growth rebounds - MSN
Earnings call transcript: Cytek Biosciences Q1 2026 sees revenue growth amid EPS miss - Investing.com
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Cytek Biosciences Inc. (CTKB) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Cytek Biosciences Q1 Earnings Call Highlights - Barchart.com
Cytek Biosciences (CTKB) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Cytek Biosciences, Inc. 1Q 2026: Revenue $44.14M, EPS ($0.15) — 10-Q Summary - TradingView
$44.1M quarter for Cytek Biosciences (NASDAQ: CTKB) as losses widen - Stock Titan
Cytek Biosciences | 10-Q: Q1 2026 Earnings Report - Moomoo
Cytek Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cytek Biosciences Q1 revenue rises 6%, slightly misses estimates - TradingView
Cytek adds 125 instruments as service revenue jumps 15% - Stock Titan
Wider loss as Cytek Biosciences (Nasdaq: CTKB) grows Q1 2026 sales - Stock Titan
Cytek Biosciences Reports First Quarter 2026 Financial Results - GlobeNewswire
Cytek Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday - MarketBeat
New Cytek Biosciences kit aims to boost high-resolution T cell analysis - Traders Union
Cytek Biosciences (NASDAQ: CTKB) details 2026 votes on board, pay and auditor - Stock Titan
[ARS] Cytek Biosciences, Inc. SEC Filing - Stock Titan
Finanzdaten der Cytek Biosciences Inc-Aktie (CTKB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytek Biosciences Inc-Aktie (CTKB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McCombe William D. | Chief Financial Officer |
Jun 02 '25 |
Buy |
2.78 |
35,000 |
97,300 |
55,746 |
0.32%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):